multi omics data (Foundation Medicine Inc)
99
Structured Review
Foundation Medicine Inc
multi omics data
Multi Omics Data, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2436 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi+omics+data/FoundationOne+CDx/pm42034603-270-30-37
Average 99 stars, based on 2436 article reviews
Multi Omics Data, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2436 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multi+omics+data/FoundationOne+CDx/pm42034603-270-30-37
Average 99 stars, based on 2436 article reviews
multi omics data - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
other:Article Title: Relationship Between Estrogen-Induced BRCA2 and Development of Gastric Cancer Article Snippet: Between December 2019 and August 2025, 47,211 novel treatments were investigated using cancer genome panel testing ( Next-Generation Sequencing:Article Title: Precision medicine in patients with advanced biliary tract cancer. Article Snippet: .. Internal/academic (e.g., MOSCATO 01/02 [22,23], MATCH-R [24,25], SHIVA [26] , BOB [NCT03767075]) or commercial Article Title: Association of sampling method and FFPE storage duration with comprehensive genomic profiling success in gastrointestinal tract cancers Article Snippet: .. CGP testing was performed using one of three NGS platforms approved for clinical use in Japan: Analysis:Article Title: Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer † Article Snippet: .. Tempus xT CDx (Tempus AI, Inc., USA), the most recently approved test for tumor-only indication [ ], and FoundationOne CDx and Foundation One Liquid CDx for Tissue:Article Title: Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA / AKT1 / PTEN -altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib Article Snippet: .. Of 708 patients randomized in the CAPItello-291 trial, 700 had tumor tissue tested by |